Raktažodžai: dirglioji šlapimo pūslė, šlapimo nelaikymas, anticholinerginiai vaistai. SantraukaTikslas. Išanalizuoti ir palyginti medikamentų, skiriamų dirgliosios šlapimo pūslės (DŠP) gydymui, efektyvumą ir DŠP sąsajas su kitomis ligomis vienoje moterų konsultacijoje. Metodika. Atliktas retrospektyvus tyrimas, kurio metu analizuoti 218 moterų, sergančių DŠP, ambulatorinių kortelių duomenys. Buvo vertinami pacienčių anamneziniai duomenys: amžius, menopauzės trukmė, gimdymų skaičius, persirgtos ligos, atliktos operacijos, šalutinė patologija. Vertintas DŠP simptomų dažnis, skiriamas gydymas ir efektyvumas. Tirta anticholinerginių vaistų efektyvumo koreliacija tarp minėtų veiksnių. Tyrime skaičiuota aprašomoji statistika ir tikrintos statistinės hipotezės apie skirtumus tarp vidurkių dažnio bei požymių tarpusavio priklausomumo. Rezultatai laikyti statistiškai reikšmingais, kai p<0,05. Rezultatai. Sergamumas arterine hipertenzija ir cukriniu diabetu neturi įtakos DŠP skubumo simptomatikai (p>0,05), tačiau sergant diabetu pacientes reikšmingai dažniau vargina nikturija (p=0,002). Statistiškai reikšmingai dažniau pacientes vargina miktutrija, kai jos turi ginekologinę patologiją (p=0,012), tačiau šlapinimosi dažnis naktį reikšmingai nesiskiria (p=0,412). Moterys, sergančios DŠP ir neurologine patologija, dažnu šlapinimusi dieną (p=0,77) ir naktį (p=0,438) skundžiasi tiek pat, kiek ir tos, kurių anamnezėje neurologinės ligos nėra. Gydymo efektyvumas nepriklauso nuo pacientės amžiaus (p=0,859), taip pat efektyvumui neturi įtakos menopauzės trukmė (p=0,846) ar gimdymų skaičius (p=0,852). Gydymo anticholinerginiais vaistais efektyvumas tarp CD sergančių ir nesergančių moterų nesiskiria (p=0,182). Gydymo solifenacinu veiksmingumas reikšmingai nesiskiria jaunesnėms nei 65 metų ir vyresnėms nei 65 metų moterims (p=1,0), tolterodino efektyvumas vienodas minėtose amžiaus grupėse (p=0,589). Ilgėjant menopauzės trukmei tolterodino efektyvumas didėja (p=0,03), o solifenacino efektyvumas nuo menopauzės trukmės nepriklauso (p=0,208).Išvados. DŠP sindromo simptomams pasireikšti reikšmin-gos įtakos turi cukrinis diabetas ir ginekologinė patologija, tuo tarpu kitos šalutinės patologijos įtakos nedaro.DŠP gydymo anticholinerginiais vaistais efektyvumas nepriklauso nuo pacientės amžiaus, menopauzės trukmės gimdymų skaičiaus ar sergamumo kitomis ligomis. ĮvadasLietuvoje nėra atliktų tyrimų apie dirgliosios šlapimo pūslės sindromo paplitimą, galimus rizikos veiksnius ir kitų ligų įtaką šiai patologijai. Taip pat nėra aprašyta nei vieno tyrimo apie medikamentinio gydymo taikymą, jo efektyvumą, nepageidaujamą poveikį. Kaip teigiama daktaro disertacijoje, tikėtina, kad to priežastis -minimalios Lietuvos gydytojų epidemiologinės žinios, kurias nulemia šlapimo nelaikymu sergančių pacientų registro nebuvimas [1]. Remiantis užsienio autorių atliktais tyrimais, vidutiniškai 30% visų moterų nesulaiko šlapimo [2][3][4]. Pasaulyje įvairių studijų duomenimis, dirgliosios šlapimo pūslės sindromo paplitimas svyruoja nuo 11,8% iki 16,6% [5].Tarptautinė...
Electronic poster abstractsthe placental adhesion or accreta, if blood flow signal overflow at the interruption suggesting placental penetration. Preoperative evaluation of the degree of AIP was performed and matched with intraoperative findings and postoperative pathology. Results: 11 cases were confirmed. 3 cases had not been delivered, and 2 cases were lost to follow-up. The average age of 11 pregnant women was 32.3 ± 5.50years, and the median gestational age was 31+2W weeks. Ten cases of placenta were extensive, the placenta was attached to the anterior and posterior walls of the uterine cavity. Among them, 7 cases>1CS, 2 cases>2 CS, 2 cases had no history of CS, 2 had a history of AIP. 7 cases, orbital uterine muscle wall echo was discontinuous, intraoperative bleeding 300-1000ml, confirmed as placental adhesion and implant, 3 cases of uterine muscle wall echo discontinuity accompanied by interruption of blood flow overflow, bleeding was 1500-2000ml. The pathological diagnosis was placental penetration, one of cases was cervical placenta accreta. One case, the uterine muscle wall and bladder wall showed parallel double-track sign, it had no adhesion and only vascular preposition. 11 cases were completely consistent with the preoperative evaluation. Conclusions: This study shows that the dual-orbital angiography and vascular spillover of 3D Crystal Vue can accurately assess the AIP. 3D Crystal Vue provides imaging evidence for personalised treatment options for AIP women.
Key words: cervicosacropexy (CESA), vaginosacropexy (VASA), urinary incontinence, overactive bladder syndrome, mixed urinary incontinence, polyvinylidene fluoride tape, uterosacral ligaments. SummaryBackground. The purpose of our study is to evaluate and present the results of the first cervicosacropexy (CESA) in Lithuania, which was performed in Klaipeda university hospital. Materials and methods. For the 62 years old female patient suffering from overactive bladder syndrome, confirmed by urodynamic test, and II⁰ pelvic organ prolapse (by pelvic organ prolapse quantification classification) cervicosacropexy using polyvinylidene fluoride (PVDF) tape was performed in Klaipeda University Hospital in 2016. Urinary incontinence was evaluated by voiding diary, International Consultation on Incontinence Modular Questionnaire -Short Form (ICIQ-SF) and Overactive Bladder Symptom Score (OABSS), that were filled by the patient before the surgery and 2, 4, 8 weeks after it. Urinary urgency, episodes of urinary incontinence, the need of sanitary pads and urinary frequency were compared before and after the surgery. To assess urinary incontinence impact on daily life, the General King's Health Questionnaire (GKHQ) was used before and after the procedure. Results. After the surgery decrease of episodes of urinary incontinence, urinary frequency during day and night, urinary urgency and the need of sanitary pads were observed. Moreover, the patient could hold the urine longer after feeling the need to urinate. IntroductionUrge urinary incontinence (UUI) is a bothersome urogenital disorder that affects approximately one third of postmenopausal women. Urgency, frequency and incontinence -this triad has detrimental effects on the patient's quality of life and proves to be a source of anxiety [1]. According to Herzog, Fultz and Thom, about 40 % of all women will develop urinary incontinence during their life, usually starting around the age of 50 [3,4]. This is a debilitating disorder, which massively restricts the social and private life of the patient [5]. Known pharmacological treatment attempts to reduce the urinary incontinence symptoms; however, there is no cure addressing the basic cause of the disease [6]. Moreover, pharmacological treatment is slightly more effective than placebo [7]. Treatment of UUI is now focused on antimuscarinic drug therapy, botulinum intravesical injection, sacral neuromodulation, and behavioral interventions [7]. Despite many known treatment methods of UUI, surgery is not widely practiced.Little is known about causes of UUI. Recent physiological and clinical researches are focused on descriptions and development of etiological theories. The most promising theories indicate abnormalities in control of bladder function resulting from aberrations of neurological signals from the bladder (sensation) as well as signals from continence controlling central and peripheral nervous system [7].In 1991 de Lancey emphasized the importance of the support of the genital tract for continence function [8]. He con...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.